Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

A

Agilent Technologies Reports 10% Revenue Growth

Agilent Technologies said second-quarter revenue rose to $1.83 billion, up 10.0% from a year earlier and 6.3% on a core basis.

Net income climbed to $339 million from $215 million in the prior-year quarter, while earnings per share increased to $1.20 from $0.75. Non-GAAP net income rose to $423 million from $373 million, and non-GAAP EPS increased to $1.49 from $1.31.

Operating margin improved as well. GAAP operating margin was 21.7%, while non-GAAP operating margin was 26.4%, up 130 basis points from a year ago and 180 basis points from the prior quarter.

By business unit, life sciences and diagnostics markets revenue increased 12% to $732 million, with 9% core growth and a 22.0% operating margin. Agilent CrossLab revenue rose 6% to $759 million, with 2% core growth and a 32.0% operating margin. Applied markets revenue increased 14% to $344 million, with 11% core growth and a 23.3% operating margin.

For fiscal 2026, Agilent raised its revenue outlook to $7.39 billion to $7.49 billion, implying reported growth of 6.3% to 7.8% and core growth of 4.5% to 6.0%. The midpoint of that range reflects a 30-basis-point increase in revenue growth guidance. The company also now expects non-GAAP operating margin expansion of 85 basis points at the midpoint, 10 basis points better than before, and non-GAAP EPS of $6.00 to $6.10, up 8 cents at the midpoint.

For the third quarter, Agilent forecast revenue of $1.83 billion to $1.85 billion, up 5.0% to 6.5% reported and 4.4% to 5.9% core, with non-GAAP EPS expected at $1.48 to $1.50. Following these announcements, the company's shares moved 0.4%, and are now trading at a price of $115.535. For the full picture, make sure to review 's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS